ES2061380B1 - Empleo del factor de crecimiento fibroblastico y sus derivados como neuroprotectores y neuromoduladores. - Google Patents

Empleo del factor de crecimiento fibroblastico y sus derivados como neuroprotectores y neuromoduladores.

Info

Publication number
ES2061380B1
ES2061380B1 ES09202360A ES9202360A ES2061380B1 ES 2061380 B1 ES2061380 B1 ES 2061380B1 ES 09202360 A ES09202360 A ES 09202360A ES 9202360 A ES9202360 A ES 9202360A ES 2061380 B1 ES2061380 B1 ES 2061380B1
Authority
ES
Spain
Prior art keywords
growth factor
neuroprotectors
neuromodulators
employment
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES09202360A
Other languages
English (en)
Other versions
ES2061380A1 (es
Inventor
Gallego Guillermo Gimenez
Sanchez Pedro Cuevas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guillermo Gimenez Gallego (titular Al 50%)
Original Assignee
Boehringer Ingelheim España SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim España SA filed Critical Boehringer Ingelheim España SA
Priority to ES09202360A priority Critical patent/ES2061380B1/es
Priority to CA002127537A priority patent/CA2127537A1/en
Priority to PCT/EP1993/003234 priority patent/WO1994012201A1/en
Priority to JP6512718A priority patent/JPH07504205A/ja
Priority to EP94901818A priority patent/EP0624094A1/en
Publication of ES2061380A1 publication Critical patent/ES2061380A1/es
Application granted granted Critical
Publication of ES2061380B1 publication Critical patent/ES2061380B1/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

EMPLEO DEL FACTOR DE CRECIMIENTO FIBROBLASTICO Y SUS DERIVADOS COMO NEUROPROTECTORES Y NEUROMODULADORES FRENTE AL DAÑO PRODUCIDO POR LA ISQUEMIA Y LA REPERFUSION CEREBRAL, ASI COMO FRENTE A LA ACTIVIDAD MOTORA Y A TODOS LOS COMPUESTOS RELACIONADOS CON LA MISMA, EN AQUELLAS SITUACIONES CLINICAS QUE REQUIERAN UNA PROTECCION NEURONAL TRAS LA ISQUEMIA CEREBRAL O CAROTIDEA. IGUALMENTE, SE JUSTIFICA EL USO FARMACOLOGICO DEL FACTOR DE CRECIMIENTO DE LOS FIBROBLASTOS ACIDOS Y BASICOS, Y DE TODOS LOS COMPUESTOS RELACIONADOS CON LOS MISMOS, EN LAS SITUACIONES CLINICAS QUE REQUIERAN UNA DISMINUCION DE LA AGITACION Y DE LA AGRESIVIDAD.
ES09202360A 1992-11-23 1992-11-23 Empleo del factor de crecimiento fibroblastico y sus derivados como neuroprotectores y neuromoduladores. Expired - Lifetime ES2061380B1 (es)

Priority Applications (5)

Application Number Priority Date Filing Date Title
ES09202360A ES2061380B1 (es) 1992-11-23 1992-11-23 Empleo del factor de crecimiento fibroblastico y sus derivados como neuroprotectores y neuromoduladores.
CA002127537A CA2127537A1 (en) 1992-11-23 1993-11-19 Use of fibroblast growth factors as neuroprotective and neuromodulatory agents
PCT/EP1993/003234 WO1994012201A1 (en) 1992-11-23 1993-11-19 Use of fibroblast growth factors as neuroprotective and neuromodulatory agents
JP6512718A JPH07504205A (ja) 1992-11-23 1993-11-19 神経保護及び神経調節の薬剤としての繊維芽細胞増殖因子の使用
EP94901818A EP0624094A1 (en) 1992-11-23 1993-11-19 Use of fibroblast growth factors as neuroprotective and neuromodulatory agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES09202360A ES2061380B1 (es) 1992-11-23 1992-11-23 Empleo del factor de crecimiento fibroblastico y sus derivados como neuroprotectores y neuromoduladores.

Publications (2)

Publication Number Publication Date
ES2061380A1 ES2061380A1 (es) 1994-12-01
ES2061380B1 true ES2061380B1 (es) 1995-07-01

Family

ID=8278876

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09202360A Expired - Lifetime ES2061380B1 (es) 1992-11-23 1992-11-23 Empleo del factor de crecimiento fibroblastico y sus derivados como neuroprotectores y neuromoduladores.

Country Status (5)

Country Link
EP (1) EP0624094A1 (es)
JP (1) JPH07504205A (es)
CA (1) CA2127537A1 (es)
ES (1) ES2061380B1 (es)
WO (1) WO1994012201A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5831117A (en) 1995-01-20 1998-11-03 G. D. Searle & Co. Method of preparing retroviral protease inhibitor intermediates
US5891848A (en) * 1995-04-25 1999-04-06 Nippon Zoki Pharmaceutical Co., Ltd. Peptide fragments
ATE493141T1 (de) * 1996-03-22 2011-01-15 Stryker Corp Verfahren zur verbesserten funktionellen erholung der motorischen koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns
CA2293492A1 (en) * 1997-06-11 1998-12-17 Martin Berry Cns neuroregenerative compositions and methods of use
AU8855798A (en) * 1997-07-03 1999-01-25 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Novel composition for treating, preventing and/or delaying ischemic cell death
JP3507884B2 (ja) * 2000-03-07 2004-03-15 新潟大学長 遺伝子発現を指標とする統合失調症の客観的診断法
ES2660765T3 (es) 2004-06-21 2018-03-26 The Board Of Trustees Of The Leland Stanford Junior University Genes y rutas expresadas de forma diferencial en trastorno bipolar y/o trastorno depresivo mayor
EP2564864B8 (en) 2005-11-12 2015-05-13 The Board of Trustees of The Leland Stanford Junior University FGF2-related methods for diagnosing and treating depression

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057494A (en) * 1988-08-03 1991-10-15 Ethicon, Inc. Method for preventing tissue damage after an ischemic episode
JP2814529B2 (ja) * 1989-03-16 1998-10-22 味の素株式会社 虚血性脳障害治療薬
AU3129793A (en) * 1991-11-08 1993-06-07 General Hospital Corporation, The Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration

Also Published As

Publication number Publication date
ES2061380A1 (es) 1994-12-01
JPH07504205A (ja) 1995-05-11
CA2127537A1 (en) 1994-06-09
WO1994012201A1 (en) 1994-06-09
EP0624094A1 (en) 1994-11-17

Similar Documents

Publication Publication Date Title
BR8904983A (pt) Dispositivo de estacao de trabalho
BR8906006A (pt) Processo e sistema para estabelecer intercomunicacao entre as aplicacoes e um administrador de base de dados e processo para ajustar as necessidades de armazenagem de um sistema de computador
BR7706125A (pt) Processo para a preparacao de poliisocianatos com estrutura de isocianurato bem como seu emprego
ES2059602T3 (es) Uso de derivados de adamantano para la prevencion y tratamiento de isquemia cerebral.
IT1073191B (it) Procedimento per la produzione di matrici da stampa planografica con raggi laser
SV1994000028A (es) Nuevas sulfonilamino pirimidinas, ref. 10916 sv.
TR23217A (tr) Tuetuen-icme esyalari ile kullanilacak,bunlarin tesirini duezelten ajan
DK64988D0 (da) Kirurgisk vaerktoej til straekning af huden
ES463409A1 (es) Procedimiento para la preparacion de nuevas fluoracil-resor-cinas sustituidas.
ES2089687T3 (es) 4-fenil-piridonas y 4-fenil-2-alcoxipiridinas sustituidas como inhibidores de la hmg-coa-reductasa.
ES8801618A1 (es) Un procedimiento para preparar derivados de arilciclobutilalquilamina
BR8605792A (pt) Processo de purificacao para altas concentracoes de carga
ES2056059T3 (es) Un metodo para preparar cefadroxil monohidrato cristalino.
ES2099879T3 (es) 5-oxo-dibenzo(a,d)ciclohepta-1,4-dienos y su uso como agentes retrovirales.
SE8009084L (sv) System for informationsskyltar
IT7820763A0 (it) Processo per la isomerizzazione di cicloesan bis (metilamina) perl'ottenimento di stereoisomeri.
ES2061380A1 (es) Empleo del factor de crecimiento fibroblastico y sus derivados como neuroprotectores y neuromoduladores.
DE69123886D1 (de) Vorsensibilisierte Platten für die Herstellung von Druckplatten für wasserlosen Offsetdruck
ES2063328T3 (es) Nuevo uso de naftoxazinas.
ATE65680T1 (de) Armaturenblock.
FR1263414A (fr) Perfectionnements à l'éclairage nocturne des cadrans gravés éclairés par la tranche
IT1224469B (it) Perfezionamenti relativi a dispositivi di bloccaggio per l'uso con organi allungati
BR8705619A (pt) Processo para inibir microorganismos
MX9307679A (es) Derivados de furanona utiles en terapia.
BE858136A (fr) Perfectionnements apportes aux supports, notamment en forme de plots, etablis en elastomere

Legal Events

Date Code Title Description
PC2A Transfer of patent

Owner name: GUILLERMO GIMENEZ GALLEGO (TITULAR AL 50%)